Updated:
AMED
Japan's central R&D funding agency, translating $1.25 billion annually into biomedical and clinical breakthroughs led by President Mishima Kazuo.
AMED
AMED launched in April 2015 as a consolidated front door for Japanese medical R&D funding, absorbing programs previously scattered across the Ministry of Education, Ministry of Health, and Ministry of Economy. Mishima Kazuo serves as its president. The agency's core mandate funnels roughly $1.25 billion annually into academic and industry partnerships (per public record), targeting bottlenecks between basic discovery and approved therapies. Its creation reflected a national recognition that Japan's fragmented grant apparatus was losing ground to centralized competitors like the NIH and UKRI. Deployment spans regenerative medicine, genomic medicine, infectious disease, oncology, neuroscience, and rare disease research. AMED's strategy mixes investigator-initiated academic grants with large-scale applied programs and public–private consortia. Flagship initiatives include the Practical Research for Innovative Cancer Control program and the Regenerative Medicine and Gene Therapy project, which co-funds translational work with pharma partners. The agency also coordinates Japan's contributions to international efforts like the International Human Frontier Science Program and the Global Alliance for Genomics and Health. AMED operates from its Tokyo headquarters and regional hubs that support clinical research trials infrastructure. It coordinates the Japanese clinical research network ARISE—connecting university hospitals, national research centers, and industry. The agency has also funded the creation of biobanks and translational research cores at institutions like Kyoto University and the RIKEN institutes. In October 2023, AMED launched a ¥20 billion moonshot-style Advanced Research Initiative for pandemic preparedness, targeting mRNA platforms and universal coronavirus vaccines (per Nature Index, 2023). The structural differentiator is AMED's single-window design: before 2015, an academic investigator seeking translational funding might need applications to three different ministries with no coordination. AMED consolidated that process and added a strategic review function modeled partly on the NIH's institute structure but adapted to Japan's consortia-oriented industrial policy. Its budget authority lets it commit multi-year funding without the annual appropriations cliff that plagued predecessor programs, giving principal investigators five-year funding horizons in some programs.
General information
Firm type
Government Agency
Year founded
2015
AUM
Undisclosed
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
Tokyo, Japan
Principals
Mishima Kazuo
President
Sector focus
Frequently asked questions
Who runs investment decisions at AMED?
President Mishima Kazuo oversees AMED's strategic allocation of its $1.25 billion annual budget. Programmatic funding decisions are guided by agency-wide review committees and scientific advisory panels composed of external experts, convened under AMED's Department of Research and Development Promotion. Major grants are peer-reviewed, with final authority resting with senior agency leadership.
How does AMED source proprietary deal flow?
AMED does not source proprietary deal flow in the investor sense, but designs directed funding calls in areas of national strategic interest such as regenerative medicine, genomic medicine, and pandemic preparedness. The agency also draws on the research pipelines of Japan's leading universities and national research institutes — University of Tokyo, Kyoto University, RIKEN — whose proposals flow into AMED's integrated grant management system.
Is AMED structured as a family office or a venture firm?
It is neither. AMED is an Incorporated Administrative Agency under the Japanese government's National Strategic Special Zone framework. It functions as a funding and coordination body for biomedical translation, blending features of a research council, a grant-making foundation, and an industrial-policy accelerator.
Does AMED participate in fund commitments or only direct grants?
AMED operates almost entirely through direct grants, contracts, and consortia funding. It does not operate as a limited partner in venture capital funds, but its programs frequently co-fund projects alongside pharmaceutical companies and medical device manufacturers under formal collaboration agreements.
What investment stages does AMED typically target?
AMED covers the full translational arc from preclinical proof-of-concept through Phase II clinical trials. Its programs are segmented by translational stage: basic science with clinical intent (AMED-CREST), applied translational projects, and clinical research trial enabling. It generally does not fund late-stage Phase III regulatory trials or commercial manufacturing.
How is AMED related to global counterparts like the NIH?
AMED was explicitly modeled in part on the NIH, but operates on a smaller scale and with a tighter focus on translational, rather than broad basic, science. It has formal memoranda of cooperation with the NIH, the UK's Medical Research Council, and Canada's CIHR, and funds Japanese participation in international collaborative programs.
Where does AMED's budget come from?
AMED's approximately $1.25 billion annual budget is appropriated by the Japanese government and draws from multiple ministries. This consolidation is AMED's core structural innovation — before 2015, similar funding was dispersed across MEXT, MHLW, and METI without coordination.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: